5,6,7,8-四氢咪唑并[1,2-a]吡嗪 | 91476-80-1

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 5,6,7,8-四氢咪唑并[1,2-a]吡嗪
• 中文别名: 5,6,7,8-四氢咪唑[1,2-a]吡嗪；5,6,7,8-四氢咪唑[1,2-A]吡嗪
• 英文名称: 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine
• 英文别名: 5H,6H,7H,8H-imidazo[1,2-a]pyrazine
• CAS: 91476-80-1
• 化学式: C₆H₉N₃
• mdl: MFCD09701264
• 分子量: 123.158
• InChiKey: SWBUHQQTIPEPMK-UHFFFAOYSA-N

物化性质

• 沸点：
  322.8±35.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5H,6H,7H,8H-imidazo[1,2-a]pyrazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 5H,6H,7H,8H-imidazo[1,2-a]pyrazine
CAS number: 91476-80-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H9N3
Molecular weight: 123.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

咪唑并[1，2-a]吡嗪是含氮杂环化合物中一种药理活性较强的合成砌块，而5,6,7,8-四氢咪唑[1,2-A]吡嗪则是常见的医药化工中间体，用于实验室研发过程。

其制备方法如下：在反应釜中加入咪唑并[1，2-a]吡嗪、二氧化铂和去离子水，并用10%的四乙基氢氧化铵将体系调至pH 12。随后进行3次氢气置换，维持氢压在1.0MPa条件下室温反应24小时。反应完成后，向反应液中加入浓盐酸进行酸化处理，过滤后将滤液减压蒸除溶剂，并使用乙醇∶10% 盐酸(1∶1)重结晶，最终得到5,6,7,8-四氢咪唑并[1,2-a]吡嗪。

反应信息

• 作为反应物：
  描述：

  5,6,7,8-四氢咪唑并[1,2-a]吡嗪 在 sodium nitrite 作用下， 以 盐酸 为溶剂， 反应 0.25h， 生成 7-亚硝基-5,6,7,8-四氢咪唑并[1,2-a]吡嗪
  参考文献：
  名称：

  Bonnet, Pierre-Antoine; Sablayrolles, Claire; Chapat, Jean-Pierre, Journal of Chemical Research, Miniprint, 1984, # 2, p. 468 - 480

  摘要：

  DOI：
• 作为产物：
  描述：

  7-benzyl-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine 在 palladium 10% on activated carbon 甲酸 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 7.0h， 生成 5,6,7,8-四氢咪唑并[1,2-a]吡嗪
  参考文献：
  名称：

  Inhibitors of JNK

  摘要：

  公式I的化合物或其药用盐，其中：其中m、n、p、q、X、Y、Z、A、R1、R2、R3、R4、R5和Y6如本文所定义。本文披露的化合物和组合物可用于调节JNK的活性并治疗与JNK活性相关的疾病。

  公开号：

  US20110301170A1
• 作为试剂：
  描述：

  吲哚[1,2-A]吡嗪 在 氧化铂 5,6,7,8-四氢咪唑并[1,2-a]吡嗪 作用下， 以 甲醇 为溶剂， 以gave the title compound (512 mg) as a viscous oil的产率得到5,6,7,8-四氢咪唑并[1,2-a]吡嗪
  参考文献：
  名称：

  NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

  摘要：

  本发明涉及抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，其在治疗或预防二肽基肽酶-IV酶涉及的疾病中具有用途，例如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶涉及的这些疾病中使用这些化合物和组合物。

  公开号：

  US20110190308A1

文献信息

• SUBSTITUTED SULFONAMIDE COMPOUNDS
  申请人：OBERBOERSCH Stefan

  公开号：US20080153843A1

  公开（公告）日：2008-06-26

  Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

  磺胺取代物，其制备方法，含有这些化合物的药物组合物，以及磺胺取代物在治疗或抑制疼痛和/或各种疾病或疾病状态中的用途。
• Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials
  作者：Neil R. Norcross、Beatriz Baragaña、Caroline Wilson、Irene Hallyburton、Maria Osuna-Cabello、Suzanne Norval、Jennifer Riley、Laste Stojanovski、Frederick R. C. Simeons、Achim Porzelle、Raffaella Grimaldi、Sergio Wittlin、Sandra Duffy、Vicky M. Avery、Stephan Meister、Laura Sanz、Belén Jiménez-Díaz、Iñigo Angulo-Barturen、Santiago Ferrer、María Santos Martínez、Francisco Javier Gamo、Julie A. Frearson、David W. Gray、Alan H. Fairlamb、Elizabeth A. Winzeler、David Waterson、Simon F. Campbell、Paul Willis、Kevin D. Read、Ian H. Gilbert

  DOI：10.1021/acs.jmedchem.6b00028

  日期：2016.7.14

  dosed orally. Unfortunately, the compound is a potent inhibitor of cytochrome P450 enzymes, probably due to a 4-pyridyl substituent. Nevertheless, this is a lead molecule with a potentially useful antimalarial profile, which could either be further optimized or be used for target hunting.

  在本文中，我们描述了基于三取代嘧啶支架的恶性疟原虫表型命中的优化。这导致在疟疾的伯氏疟原虫小鼠模型中具有良好药代动力学和口服活性的化合物。在疟疾的伯氏疟原虫小鼠模型中，当每天口服30 mg / kg连续4天时，最有希望的化合物（13）表现出96％的寄生虫病降低。它也证明了在口服SCID小鼠模型中，ED90为11.7 mg / kg时，恶性疟原虫红细胞阶段的清除率较快。不幸的是，该化合物可能是4-吡啶基取代基，是细胞色素P450酶的有效抑制剂。然而，这是具有潜在有用的抗疟谱的先导分子，可以进一步优化或用于靶标狩猎。
• [EN] THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS<br/>[FR] THIÉNOPYRIDINE CARBOXAMIDES UTILISÉS COMME INHIBITEURS DE PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2017139778A1

  公开（公告）日：2017-08-17

  The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula (I), where R1, R2, R3, R4, R5, R5', R6, R7, X, m, and n are described herein.

  该披露涉及抑制剂USP28和/或USP25，用于治疗癌症、炎症、自身免疫疾病和传染病，具有式(I)，其中R1、R2、R3、R4、R5、R5'、R6、R7、X、m和n如本文所述。
• Integrated Platform for Expedited Synthesis–Purification–Testing of Small Molecule Libraries
  作者：Aleksandra Baranczak、Noah P. Tu、Jasmina Marjanovic、Philip A. Searle、Anil Vasudevan、Stevan W. Djuric

  DOI：10.1021/acsmedchemlett.7b00054

  日期：2017.4.13

  introduction of automation, leading to shortened discovery cycle times. Herein, we describe a platform that consolidates synthesis, purification, quantitation, dissolution, and testing of small molecule libraries. The system was validated through the synthesis and testing of two libraries of binders of polycomb protein EED, and excellent correlation of obtained data with results generated through conventional

  通过引入自动化可以大大提高药物化学程序的生产率，从而缩短发现周期。在这里，我们描述了一个平台，可巩固小分子文库的合成，纯化，定量，溶解和测试。该系统通过合成和测试聚梳蛋白EED的两个粘合剂库进行了验证，并且观察到获得的数据与通过常规方法生成的结果具有极好的相关性。完全自动化和集成的平台可基于多种化学转化进行批处理支持的化合物合成，并以多种生化分析形式进行测试。库的周转时间在24到36小时之间，并且值得注意的是，
• SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS
  申请人：Dahmann Georg

  公开号：US20130023502A1

  公开（公告）日：2013-01-24

  The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R 1 , R 2 , R 4 , R 3 , R 5 and R 6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

  该发明涉及公式1中的新取代吡啶基嘧啶化合物， 其中环A是一个含有五个成员的饱和或不饱和碳环，该环可选地包含一个、两个或三个异原子，每个异原子独立地选自N、S和O组成， 其中R1、R2、R4、R3、R5和R6如权利要求书中所定义，并且环A进一步可选地被一个或两个进一步取代基取代，以及上述化合物的药用盐、二对映体、对映体、消旋体、水合物和溶剂化合物。